AbbVie Overview
Company: | AbbVie |
---|---|
CEO: | Mr. Robert A. Michael CPA |
Founded: | 2013 |
Symbol: | ABBV |
Exchange: | NYSE |
Industry: | Drug Manufacturers - General |
Sector: | Healthcare |
About |
AbbVie discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant torease tear production, as well as other eye care products. AbbVie has a research collaboration with Dragonfly Therapeutics The company wasorporated in 2012 and is headquartered in North Chicago, Illinois. |
-
Ranking:
4 among 2858 companies
-
Address:
1 North Waukegan Road
-
City | State | Country:
North Chicag... | IL |
US
-
Phone:
847 932 7900
- Website:
AbbVie (ABBV)
- Stock Price
- Volume
- 1D
- 1W
- 1M
- 3M
- 6M
- YTD
- 1Y
- 2Y
- 5Y
- 10Y
- ALL
AbbVie’s revenue by segment: Alphagan/Combigan: $248.00 M, Botox Cosmetic: $2.72 B, Botox Therapeutic: $3.28 B, Duodopa: $447.00 M, H U M I R A: $8.99 B, Imbruvica: $3.35 B, Juvederm Collection: $1.18 B, Linzess/Constella: $954.00 M, Lumigan/Ganfort: $429.00 M, MAVYRET: $1.31 B, Other Aesthetics: $1.28 B, Other Eye Care: $847.00 M, Other Neuroscience: $338.00 M, Other Products: $3.03 B, Ozurdex: $494.00 M, Qulipta: $658.00 M, Restasis: $224.00 M, RINVOQ: $5.97 B, SKYRIZI: $11.72 B, Ubrelvy: $1.01 B, VENCLEXTA: $2.58 B, and Vraylar: $3.27 B in 2024.
Income Statement
Assets & Liabilities | Cash Flow
Ratios
Profitability
Valuation
AbbVie;ABBV;https://bullfincher.io/logos/us/ABBV.png;abbvie | 56334000000.00 |
---|---|
Eli Lilly and Company;LLY;https://bullfincher.io/logos/us/LLY.png;eli-lilly-and-company | 45042700000.00 |
Johnson & Johnson;JNJ;https://bullfincher.io/logos/us/JNJ.png;johnson-johnson | 88821000000.00 |
Merck & Co.;MRK;https://bullfincher.io/logos/us/MRK.png;merck-co | 64168000000.00 |
Amgen;AMGN;https://bullfincher.io/logos/us/AMGN.png;amgen | 33424000000.00 |
Frequently Asked Questions
When was AbbVie founded?
AbbVie was founded on 2013, which makes the company 12 years old.
Who is the CEO of AbbVie?
Mr. Robert A. Michael CPA is the CEO of AbbVie.
What industry and sector is AbbVie in?
AbbVie operates in the Drug Manufacturers - General industry and the Healthcare sector.
What are AbbVie's CIK, SIC, and ISIN codes?
- CIK (Central Index Key): 0001551152
- SIC (Standard Industrial Classification): 2834
- ISIN (International Securities Identification Number): US00287Y1091
How many employees does AbbVie have?
AbbVie has 55,000 employees.
What is the revenue of AbbVie?
In fiscal year 2024, AbbVie generated a revenue of $56.33 Billion.
What is the net income of AbbVie?
In fiscal year 2024, AbbVie reported a net income of $4.28 Billion.
What is AbbVie's biggest product segment?
SKYRIZI is AbbVie's biggest product segment, representing 21.57% of its total revenue.
When was AbbVie listed on the stock exchange?
AbbVie went public on Jan 2, 2013, through its Initial Public Offering (IPO), and it has been 12 years since then.
What is the ticker symbol of AbbVie, and where is it listed?
AbbVie's ticker symbol is ABBV, and the company is listed on the NYSE stock market exchange.
What is AbbVie's current stock price?
AbbVie's current stock price is $187.28 as of Jun 3, 2025.
What is AbbVie's ranking in the world?
Ranked #4among 2,858 companies based on market cap.
Who are the top competitors of AbbVie?
Competitors of AbbVie include Eli Lilly and Company, Johnson & Johnson and Merck & Co., and more.